Novartis AG
Change company Symbol lookup
Select an option...
NVS Novartis AG
SATS EchoStar Corp
$DJI Dow Jones Industrials
TIKK Tel-Instrument Electronics Corp
TEAM Atlassian Corporation PLC
PAYX Paychex Inc
FISV Fiserv Inc
PYPL PayPal Holdings Inc
PG Procter & Gamble Co

Health Care : Pharmaceuticals | Large Cap Blend
Based in Switzerland
Company profile

Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Day's Change
1.20 (1.33%)
B/A Size
Day's High
Day's Low

Today's volume of 574,476 shares is on pace to be much lighter than NVS's 10-day average volume of 2,601,086 shares.


Pancreatic Cancer Action Network Announces New Industry Partner To Accelerate New Therapies To Market Through Precision Promise Clinical Trial Platform

1:50 pm ET October 28, 2020 (PR Newswire) Print

Patient advocacy organization, Pancreatic Cancer Action Network (PanCAN) has announced plans to collaborate with the global healthcare company, Novartis, to accelerate pancreatic cancer therapies to market through PanCAN's adaptive clinical trial platform, Precision PromiseSM. PanCAN's Precision Promise aims to revolutionize the clinical development paradigm in pancreatic cancer by enabling a faster, more efficient, and patient-centric approach to developing new treatment options and improving outcomes for pancreatic cancer patients.

Pancreatic cancer is the world's toughest cancer with an overall five-year survival rate of just 10 percent. It is currently the third leading cause of cancer-related death in the U.S., underscoring the urgent need for new treatment options and research discoveries in this space.

"Traditionally, clinical trial designs have been slow to evaluate new treatment options, but with more than 57,000 Americans expected to be diagnosed with pancreatic cancer this year, it's clear that patients just can't wait," said Julie Fleshman, JD, MBA, PanCAN's president and CEO. "By initiating this partnership with Novartis, we hope to accelerate progress in the field and discover meaningful new treatment options for the patient population."

"At Novartis Oncology, our focus is on the development of transformative medicines that address some of cancer's most difficult treatment challenges," said Jeff Legos, Senior Vice President and Head of Oncology Drug Development. "We share PanCAN's goal of accelerating the drug development process and recognize the urgency and need for people diagnosed with pancreatic cancer. We look forward to learning how the innovations that are the basis of the PanCAN adaptive clinical trial platform will help us reimagine medicine and achieve our common goal: to deliver more for patients."

PanCAN's novel clinical trial platform is designed to more efficiently test new therapies, including potential new drug combinations from Novartis, for their effectiveness in treating patients with pancreatic cancer by requiring fewer patients to understand if a potential new therapy is working. The statistical design of Precision Promise was led by renowned statistician Dr. Donald Berry (Berry Consulting), who designed the I-SPY breast cancer trials and has over 400 peer-reviewed publications. Through a collaboration that involves PanCAN, leading pancreatic cancer scientists and clinicians, Berry Consulting and industry partners, with guidance from the U.S. Food and Drug Administration (FDA), Precision Promise represents a platform that can accelerate late stage development by up to two years.

About the Pancreatic Cancer Action NetworkThe Pancreatic Cancer Action Network (PanCAN), a 501(C)3 nonprofit organization, is dedicated to fighting the world's toughest cancer. In our urgent mission to save lives, we attack pancreatic cancer on all fronts: research, clinical initiatives, patient services and advocacy. Our effort is amplified by a nationwide network of grassroots support. We are determined to improve outcomes for today's patients and those diagnosed in the future.

Learn more at Follow the Pancreatic Cancer Action Network on Twitter, Instagram, and Facebook.

Media Contact: Jillian Scholten Pancreatic Cancer Action Network Direct: +1-310-706-3360 | E-mail:

View original content to download multimedia:

SOURCE Pancreatic Cancer Action Network

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.